Repositorio Dspace

Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy

Mostrar el registro sencillo del ítem

dc.contributor.author Villaverde-González, Ramón
dc.date.accessioned 2025-11-20T12:50:35Z
dc.date.available 2025-11-20T12:50:35Z
dc.date.issued 2022
dc.identifier.citation Villaverde-González R. Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy. DNND. enero de 2022;Volume 12:1-21.
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21825
dc.description.abstract Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, and degenerative disease that is up to three times more frequent in young women. MS does not alter fertility and has no impact on fetal development, the course of pregnancy, or childbirth. The Pregnancy in Multiple Sclerosis Study in 1998 showed that pregnancy, mostly in untreated women, did not adversely affect MS, as disease activity decreased during pregnancy (although it significantly increased in the first trimester postpartum). These findings, together with the limited information available on the potential risks of fetal exposure to disease modifying treatments (DMTs), meant that women were advised to delay the onset of DMTs, stop them prior to conception, or, in case of unplanned pregnancy, discontinue them when pregnancy was confirmed. Now, many women with MS receive DMTs before pregnancy and, despite being considered a period of MS stability, up to 30% of patients could relapse in the first trimester postpartum. Factors associated with an increased risk of relapse and disability during pregnancy and postpartum include relapses before and during pregnancy, a greater disability at the time of conception, the occurrence of relapses after DMT cessation before conception, and the use of high-efficacy DMTs before conception, especially natalizumab or fingolimod. Strategies to prevent postpartum activity are needed in some patients, but consensus is lacking regarding the therapeutic strategies for women with MS of a fertile age. This, along with the increasing number of DMTs, means that the decision-making processes in aspects related to family planning and therapeutic strategies before, during, and after pregnancy are increasingly more complex. The purpose of this review is to provide an update on pregnancy-related issues in women with MS, including recommendations for counseling, general management, use of DMTs in pre-pregnancy, pregnancy, and postpartum periods, and breastfeeding-related aspects of DMTs.
dc.language.iso eng
dc.publisher DOVE MEDICAL PRESS LTD
dc.rights Atribución-NoComercial 3.0 No portada
dc.rights.uri http://creativecommons.org/licenses/by-nc/3.0/ *
dc.title Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 35023987
dc.relation.publisherversion https://www.dovepress.com/updated-perspectives-on-the-challenges-of-managing-multiple-sclerosis--peer-reviewed-fulltext-article-DNND
dc.identifier.doi 10.2147/DNND.S203406
dc.journal.title Degenerative Neurological and Neuromuscular Disease
dc.identifier.essn 1179-9900


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 3.0 No portada Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 3.0 No portada

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta